Analysis of Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars - aVenture Research
Insight, China's Pharmaceutical Industry
Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars
Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA: 600867) and Huisheng Biopharmaceutical Co., Ltd. announced a Commercialization Cooperation Agreement to jointly advance diabetes treatment in China. Under the agreement, Tonghua Dongbao secured exclusive commercialization rights in Mainland China for Huiyoujia (Insulin Degludec/Insulin Aspart) and Huiyouda (Insulin Degludec)—the first domestically produced biosimilars of these next‑generation basal insulins.
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.